BRPI0407574A - combinações farmacêuticas que compreendem um inibidor de nos e um antagonista de receptor de nmda - Google Patents

combinações farmacêuticas que compreendem um inibidor de nos e um antagonista de receptor de nmda

Info

Publication number
BRPI0407574A
BRPI0407574A BRPI0407574-9A BRPI0407574A BRPI0407574A BR PI0407574 A BRPI0407574 A BR PI0407574A BR PI0407574 A BRPI0407574 A BR PI0407574A BR PI0407574 A BRPI0407574 A BR PI0407574A
Authority
BR
Brazil
Prior art keywords
receptor antagonist
nmda receptor
pharmaceutical combinations
nos inhibitor
inhibitor
Prior art date
Application number
BRPI0407574-9A
Other languages
English (en)
Inventor
John Adams Lowe Iii
Robert Alfred Volkmann
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0407574A publication Critical patent/BRPI0407574A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMBINAçõES FARMACêUTICAS QUE COMPREENDEM UM INIBIDOR DE NOS E UM ANTAGONISTA DO RECEPTOR DE NMDA". A presente invenção refere-se a métodos de tratamento de doenças neurodegenerativas e de inibição de danos neurológicos, compreendendo administrar a um paciente em necessidade de tal tratamento, um inibidor de N-NOS em combinação com um antagonista do receptor de NMDA.
BRPI0407574-9A 2003-02-18 2004-02-09 combinações farmacêuticas que compreendem um inibidor de nos e um antagonista de receptor de nmda BRPI0407574A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/368,237 US20030232739A1 (en) 2001-08-15 2003-02-18 Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
PCT/IB2004/000410 WO2004073712A1 (en) 2003-02-18 2004-02-09 Pharmaceutical combinations comprising a nos inhibitor and an nmda receptor antagonist

Publications (1)

Publication Number Publication Date
BRPI0407574A true BRPI0407574A (pt) 2006-02-14

Family

ID=32907637

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407574-9A BRPI0407574A (pt) 2003-02-18 2004-02-09 combinações farmacêuticas que compreendem um inibidor de nos e um antagonista de receptor de nmda

Country Status (6)

Country Link
US (2) US20030232739A1 (pt)
EP (1) EP1596861A1 (pt)
BR (1) BRPI0407574A (pt)
CA (1) CA2515567A1 (pt)
MX (1) MXPA05008724A (pt)
WO (1) WO2004073712A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG160342A1 (en) * 2005-02-21 2010-04-29 Proximagen Ltd Inhibition or treatment of dyskinesia
WO2012042539A2 (en) 2010-09-28 2012-04-05 Panacea Biotec Ltd Novel bicyclic compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
CA2197451C (en) * 1994-08-18 2001-01-23 Bertrand L. Chenard Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives
WO1996021445A1 (en) * 1995-01-13 1996-07-18 The General Hospital Corporation Methods of inhibiting neurodegenerative diseases
PL329195A1 (en) * 1996-03-29 1999-03-15 Pfizer Derivatives of 6-phenylpyridol-2-amine
ES2224354T3 (es) * 1997-02-10 2005-03-01 Pfizer Products Inc. Piridinas 2-amino-6-(4-fenoxi-2-sustituido)sustituidas.
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DOP2002000467A (es) * 2001-10-10 2003-04-15 Pfizer Prod Inc 2-amino-6 (fenilo sustituido en las posiciones 2,4,5)-piridinas

Also Published As

Publication number Publication date
US20030232739A1 (en) 2003-12-18
US20060058267A1 (en) 2006-03-16
MXPA05008724A (es) 2005-09-20
CA2515567A1 (en) 2004-09-02
WO2004073712A1 (en) 2004-09-02
EP1596861A1 (en) 2005-11-23

Similar Documents

Publication Publication Date Title
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
EA201100544A1 (ru) Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
HK1091127A1 (en) Compounds and methods for downregulating the effects of tgf-beta
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
BRPI0518228B8 (pt) inibidores de cinesina mitótica e uso dos mesmos
TR201907874T4 (tr) Düşük sülfat fukanlar kullanarak fibröz yapışmaları ya da inflamatuar hastalıkları inhibe etmeye yönelik farmasötik kompozisyonlar ve yöntemler.
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
CY1108201T1 (el) Συσκευες διαδερματικης απελευθερωσης οπιοειδους που ειναι ανθεκτικες στην παραβιαση
BRPI0512500A (pt) tratamento ou condições envolvendo desmielinação
TW200733976A (en) Method for the treatment of cognitive dysfunction
MY153669A (en) Ocular allergy treatments field of the invention
CY1110373T1 (el) Συνεργιστικος συνδυασμος που περιλαμβανει ροφλουμιλαστη και εναν αντιχολινεργικο παραγοντα που επιλεγεται απο αλατα τιοτροπιου για την θεραπεια αναπνευστικων ασθενειων
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
GB0002336D0 (en) Medicaments
BRPI0411347A (pt) combinações terapêuticas compreendendo inibidores de pde e antagonistas dos receptores de vasopressina para o tratamanento de dismenorréia
MXPA04011835A (es) Tratamiento de combinacion para la depresion y ansiedad.
EA200970353A1 (ru) Комбинированное лекарственное средство
MX2007007206A (es) Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos.
GB0020504D0 (en) Therapeutic method
YU57803A (sh) Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja
MXPA05010161A (es) Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias.
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]